Badia-Ramentol, J;
Gimeno-Valiente, F;
Duréndez, E;
Martínez-Ciarpaglini, C;
Linares, J;
Iglesias, M;
Cervantes, A;
... Tarazona, N; + view all
(2023)
The prognostic potential of CDX2 in colorectal cancer: Harmonizing biology and clinical practice.
Cancer Treatment Reviews
, 121
, Article 102643. 10.1016/j.ctrv.2023.102643.
Preview |
PDF
1-s2.0-S0305737223001366-main.pdf - Published Version Download (5MB) | Preview |
Abstract
Adjuvant chemotherapy following surgical intervention remains the primary treatment option for patients with localized colorectal cancer (CRC). However, a significant proportion of patients will have an unfavorable outcome after current forms of chemotherapy. While reflecting the increasing complexity of CRC, the clinical application of molecular biomarkers provides information that can be utilized to guide therapeutic strategies. Among these, caudal-related homeobox transcription factor 2 (CDX2) emerges as a biomarker of both prognosis and relapse after therapy. CDX2 is a key transcription factor that controls intestinal fate. Although rarely mutated in CRC, loss of CDX2 expression has been reported mostly in right-sided, microsatellite-unstable tumors and is associated with aggressive carcinomas. The pathological assessment of CDX2 by immunohistochemistry can thus identify patients with high-risk CRC, but the evaluation of CDX2 expression remains challenging in a substantial proportion of patients. In this review, we discuss the roles of CDX2 in homeostasis and CRC and the alterations that lead to protein expression loss. Furthermore, we review the clinical significance of CDX2 assessment, with a particular focus on its current use as a biomarker for pathological evaluation and clinical decision-making. Finally, we attempt to clarify the molecular implications of CDX2 deficiency, ultimately providing insights for a more precise evaluation of CDX2 protein expression.
| Type: | Article |
|---|---|
| Title: | The prognostic potential of CDX2 in colorectal cancer: Harmonizing biology and clinical practice |
| Location: | Netherlands |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/j.ctrv.2023.102643 |
| Publisher version: | http://dx.doi.org/10.1016/j.ctrv.2023.102643 |
| Language: | English |
| Additional information: | © 2023 The Authors. Published by Elsevier Ltd. under a Creative Commons license (http://creativecommons.org/licenses/by/4.0/). |
| Keywords: | Humans, Prognosis, Biomarkers, Tumor, Colorectal Neoplasms, Neoplasm Recurrence, Local, CDX2 Transcription Factor, Biology |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > CRUK Cancer Trials Centre |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10192393 |
Archive Staff Only
 |
View Item |
